TenSixteen Bio
Biotechnology Research • 
Lafayette, California, United States • 1-10 Employees
Company overview
| Headquarters | Lafayette, California, United States |
| Website | |
| NAICS | 541714 |
| Founded | 2020 |
| Employees | 1-10 |
| Socials |
Key Contact at TenSixteen Bio
Shukurah Atanda
Owner
About TenSixteen Bio
TenSixteen Bio is the first company to leverage somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases. We are a precision platform therapeutics company utilizing novel genomic biology across multiple disease areas. TenSixteen was conceived around the promise of leveraging unique data assets and capabilities to drive discovery and novel clinical development paradigms, and we are building a genomics and data science platform that will enable data integration and generation to support these efforts. We aim to transform the future of precision medicine in complex diseases.
TenSixteen Bio revenue & valuation
| Annual revenue | $3,000,000 |
| Revenue per employee | $750,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $9,600,000 |
| Total funding | $40,000,000 |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
United Kingdom
Canada
Spain
Frequently asked questions
4.8
40,000 users
